Evofem Biosciences, INC. (EVFM) — DEF 14A Filings
All DEF 14A filings from Evofem Biosciences, INC.. Browse 1 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (1)
-
Evofem Eyes Nasdaq Re-listing, Reverse Split Amidst Product Growth Push
— Oct 29, 2025 Risk: high
Evofem Biosciences, Inc. (EVFM) is strategically focused on increasing net product sales of PHEXX and SOLOSEC, expecting a continuation of its four consecutive
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX